Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: Data from international pharmacogenetic cohorts

Grants

Funding Acknowledgements

The study was supported in the past by a Pfizer Neuroscience Grant (C.S.) and a grant from the Victor Hurley Foundation of Melbourne Health (C.S.). A Bio21 Fellowship (C.S.), University of Melbourne fostered the international collaboration. The work was also partly supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project no. CUHK4466/06M) (P.K., L.B., T.J.O.). BioGrid Australia was responsible for database management. Dr. Nick Lawn enrolled the patients from the Royal Perth Hospital, Western Australia.We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.Disclosure: C.S. has received a Pfizer Neuroscience Grant. T.J.O. has received financial support for his research from the NH&MRC (Australia), NARSAD (U.S.A.), DEST (Australia), The Royal Melbourne Hospital Neuroscience Foundation, The Victorian Neurotrauma Initiative, and research and educational grants from the Pharmaceutical Industry (Pfizer, UCB, Jansen-Cilag, GSK, Abbott, Sanofi-Aventis). In addition he is on a Medical Advisory Board for Jansen-Cilag (Australia) and Pfizer (Australia), work for which he has received Honoraria. L.J.S. has received financial support from the Murdoch Childrens Research Institute for this research. He is a director of a pharmacogenetic testing company, which does not do genetic testing for ABCB1. Other authors report no conflict of interest.